Bacterial Sepsis

Updated: Feb 03, 2023
Author: Amber Mahmood Bokhari, MBBS; Chief Editor: Michael Stuart Bronze, MD 

Overview

Practice Essentials

Definitions

Sepsis is a life-threatening syndrome usually caused by bacterial infection. Sepsis is a response of the body's immune system that results in organ dysfunction or failure. The systemic inflammatory response syndrome (SIRS) criteria were recently replaced by the quick Sequential Organ Failure Assessment (qSOFA) in 2016, allowing for quick bedside analysis of organ dysfunction in patients with suspected or documented infection. The qSOFA score includes a respiratory rate of 22 breaths/minute or more, systolic blood pressure of 100 mm Hg or less, and altered level of consciousness. A score >2 is associated with poor outcomes. However, due to conflicting data on diagnosing sepsis it has fallen out of favor in the 2021 Sepsis guidelines and may be deemed a predictive tool rather than a diagnostic one.[1, 2, 3] For completeness, severe sepsis is defined as sepsis complicated by organ dysfunction. The definitions of sepsis and septic shock were revised in 2001 and 2021 by the Society of Critical Care Medicine and European Society of Intensive Care Medicine[1, 4] ; qSOFA and NEWS (National Early Warning Score) are the most used. NEWS is derived from measurement of respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or confusion, and temperature. A score between 0-4 is low risk, 5-6 is medium risk and 7 or higher is associated with high risk for sepsis-associated mortality.[1]  Early identification of sepsis scores including NEWS (National Early Warning Score), MEWS (Modified Early Warning Score) and SIRS were found to be more reliable and predictive than qSOFA. 

Multiple organ dysfunction syndrome (MODS) is characterized by progressive organ dysfunction in a severely ill patient, with failure to maintain homeostasis without intervention such as pressors or IV fluids. It is the end stage in infectious conditions (sepsis, septic shock) and noninfectious conditions (eg, SIRS due to pancreatitis). The greater the number of organ failures, the higher the mortality risk, with the greatest risk associated with respiratory failure requiring mechanical ventilation.

MODS can be classified as primary or secondary.[5]  Primary MODS is the direct result of identifiable injury or insult with early organ dysfunction (eg, renal failure due to a nephrotoxic agent or liver failure due to a hepatotoxic agent).

Secondary MODS is organ failure that has no attributable cause and is a consequence of the host's response (eg, acute respiratory distress syndrome [ARDS] in individuals with pancreatitis).

The following parameters are used to assess individual organ dysfunction:

  • Respiratory system: Partial pressure of arterial oxygen (PaO 2)/fraction of inspired oxygen (FiO 2) ratio
  • Hematology: Platelet count, coagulation panel (prothrombin time and partial thromboplastin time)
  • Liver: Serum bilirubin
  • Renal: Serum creatinine (or urine output)
  • Brain: Glasgow coma score
  • Cardiovascular: Hypotension and vasopressor requirement

Septic shock is defined as sepsis with hypotension requiring vasopressor therapy to maintain a mean blood pressure of more than 65 mm Hg and a serum lactate level exceeding 2 mmol/L (18 mg/dL) after adequate fluid resuscitation.[2] This has a greater risk for mortality and long-term morbidity.

Pseudosepsis is defined as fever, leukocytosis, and hypotension due to causes other than sepsis. Examples might include the clinical picture seen with salicylate intoxication, methamphetamine overdose, or bilateral adrenal hemorrhage.

Etiology

Sepsis can be caused by an obvious injury or infection or a more complicated etiology such as perforation, compromise, or rupture of an intra-abdominal or pelvic structure.[6] Other etiologies can include meningitis, head and neck infections, deep neck space infections, pyelonephritis, renal abscess (intrarenal or extrarenal), acute prostatitis/prostatic abscess, severe skin or skin structure infections (eg, necrotizing fasciitis), postsurgical infections, or systemic infections such as rickettsial infection. A more detailed discussion of sepsis etiology in various organ systems is provided in Etiology.

Clinical Presentation

Individuals with sepsis may present with localizing symptoms related to a specific site or source of infection or may present with nonspecific symptoms. Individuals with nonspecific symptoms are usually acutely ill with fever and may present with or without shaking chills. Mental status may be impaired in the setting of fever or hypotension. Patients with bacteremia from any source often display an increased breathing rate resulting in respiratory alkalosis. The skin of patients with sepsis may be warm or cold, depending on the adequacy of organ and skin perfusion. A detailed history and physical examination is essential in determining the likely source of the septic process. This helps the clinician to determine the appropriate treatment and antimicrobial therapy.

See Clinical Presentation, History and Physical Examination, and Treatment for more detail.

Diagnosis

A diagnosis of sepsis is based on a detailed history, physical examination, laboratory and microbiology testing, and imaging studies. 

Laboratory studies that may be considered include the following:

  • Complete blood count (CBC) - May show elevated or low white blood cell count, anemia, and/or thrombocytopenia
  • Chemistry studies, such as markers of liver or kidney injury - May suggest organ dysfunction
  • Bacterial cultures - Blood cultures and site-specific cultures based on clinical suspicion (eg, wound culture, sputum culture, or urine culture)
  • Stained buffy coat smears or Gram staining of peripheral blood - May be helpful in certain infections
  • Urine studies (urinalysis, microscopy, urine culture)
  • Certain biomarkers, such as procalcitonin [7, 8, 9] and presepsin [10] - May be useful in diagnosing early sepsis and in determining prognosis

Imaging modalities should be focused on areas of clinical concern, based on the history and physical examination, and may include the following:

  • Chest radiography (to rule out pneumonia and diagnose other causes of pulmonary infiltrates)
  • Chest CT scanning (to further evaluate for pneumonia or other lung pathology)
  • Abdominal ultrasonography (for suspected biliary tract obstruction)
  • Abdominal CT scanning or MRI (for assessing a suspected non-biliary intra-abdominal source of infection or delineating intrarenal and extrarenal pathology)
  • Site-specific soft tissue imaging, including ultrasonography, CT scanning, or MRI (to assess for possible abscess, fluid collection, or necrotizing skin infection)
  • Contrast-enhanced CT scanning or MRI of the brain/neck (to assess for possible masses, abscess, fluid collection, or necrotizing infection)

The following cardiac studies may be useful if cardiac involvement or disease is suspected as a cause or complication of infection:

  • Electrocardiography (ECG) to evaluate for conduction abnormalities or delays or arrhythmias; pericarditis may be a cause of “pseudosepsis”
  • Cardiac enzyme levels
  • Echocardiography to evaluate for structural heart disease

Invasive diagnostic procedures that may be considered include the following:

  • Thoracentesis (in patients with pleural effusion)
  • Paracentesis (in patients with ascites)
  • Drainage of fluid collections/abscesses
  • Bronchoscopy with washing, lavage, or other invasive sampling (in patients with suspected pneumonia)

See Workup for more detail.

Management

Initial management may include the following[1] :

  • Inpatient admission or ICU admission for monitoring and treatment
  • Initiation of empiric antibiotic therapy, to be followed by focused treatment based on culture, laboratory, and imaging data
  • Supportive therapy as necessary to maintain organ perfusion and respiration; timely intervention with infection source control, hemodynamic stabilization, and ventilatory support
  • Transfer if requisite facilities are not available at the admitting hospital

Appropriate empiric antimicrobial therapy depends on adequate coverage of the presumed pathogen(s) responsible for the septic process, potential antimicrobial resistance patterns, and patient-specific issues such as drug allergies or chronic medical conditions. Tying sites of infection to specific pathogens should occur, as follows:

  • Intravenous line infections: Consider broad-spectrum coverage for gram-positive organisms, especially methicillin-resistant Staphylococcus aureus (MRSA) (linezolid, vancomycin, or daptomycin) and gram-negative nosocomial pathogens (especially Pseudomonas species and other Enterobacteriaceae [piperacillin-tazobactam, carbapenems, or cefepime]), and line removal. Some of these may be Candida infections.
  • Biliary tract infections: Typical bacterial agents include Enterobacteriaceae, gut-associated anaerobes, and Enterococcus. Consider carbapenems, piperacillin-tazobactam, cephalosporins, or quinolones in combination with an anaerobic agent such as metronidazole.
  • Intra-abdominal and pelvic infections: Typically Enterobacteriaceae, gut-associated anaerobes, or Enterococcus (carbapenems, piperacillin-tazobactam, or cephalosporins or quinolones in combination with an anaerobic agent such as metronidazole)
  • Urosepsis: Typically Enterobacteriaceae or Enterococcus (carbapenems, piperacillin-tazobactam, cephalosporins, quinolones, or aminoglycosides)
  • Pneumococcal sepsis: Third-generation cephalosporins, respiratory quinolone (levofloxacin or moxifloxacin), carbapenem, or vancomycin if resistance is suspected
  • Sepsis of unknown origin: Meropenem, imipenem, piperacillin-tazobactam, or tigecycline; metronidazole plus levofloxacin, cefepime, or ceftriaxone may be alternatives

Early surgical evaluation for presumed intra-abdominal or pelvic sepsis is essential. Procedures that may be warranted depend on the source of the infection, the severity of sepsis, and the patient’s clinical status, among other factors.

Once an etiologic pathogen is identified, typically via culture, narrowed antibiotic therapy against the identified pathogen is appropriate (eg, penicillin for penicillin-susceptible Streptococcus pneumoniae).

See Treatment and Medication for more detail.

Background

Hippocrates, in the fourth century BCE, used the term sepsis denoting decomposition. Avicenna, in the eleventh century, called diseases causing purulence as blood rot. In the nineteenth century, the term sepsis was widely used to describe severe systemic toxicity. A closely derived term of septicemia was used for bacterial infection in the blood, which has been replaced by the term bacteremia. In the last 2 centuries, the processes underlying infections have been better studied and elucidated. The role of microorganisms in causing infections and the intricate mechanisms of various intrinsic and extrinsic toxins in damaging body tissues that result in fever and shock has been discovered with painstaking research. At the beginning of the twentieth century, the term endotoxin was devised by Pfeiffer to explain the causative agent in infection with cholera. It was later linked to other gram-negative bacterial pathogenicity.[11]

The initial sepsis guidelines were published in 2004 and revised in 2008 and 2012. The current clinical practice guidelines are a revision of the 2012 Surviving Sepsis Campaign (SSC) guidelines for the management of severe sepsis and septic shock. See Guidelines for more detail.

Etiology

The etiology of sepsis is diverse, and clinical clues to various organ systems aid in appropriate workup and diagnosis. It is pertinent to be able to distinguish between the infectious and noninfectious causes of fever in a septic patient. The following are organ system–specific etiologies of possible sepsis:

  • Skin/soft tissue: Necrotizing fasciitis, cellulitis, myonecrosis, or gas gangrene, among others, with erythema, edema, lymphangitis and positive skin biopsy result
  • Wound infection: Inflammation, edema, erythema, discharge of pus, with positive Gram stain and culture results from incision and drainage or deep cultures
  • Upper respiratory tract: Pharyngitis, tonsillitis, or sinusitis, among others, with inflammation, exudate with or without swelling, and lymphadenopathy or positive throat swab culture or rapid test result
  • Lower respiratory tract:  Pneumonia, empyema, or lung abscess, among others, with productive cough, pleuritic chest pain, consolidation on auscultation, positive sputum culture result, positive blood culture result, rapid viral testing, urinary antigen testing (eg, Pneumococcus, Legionella), quantitative culture of protected brush, or bronchoalveolar lavage
  • Central nervous system: Meningitis, brain abscess, or infected hematoma, among others, with signs of meningeal irritation, elevated CSF cell count and protein level, reduced CSF glucose level, positive Gram stain and culture results
  • Cerebrovascular system: Myocardial infarction, acute valvular dysfunction, myocarditis, pericarditis, ruptured aortic aneurysm, aortitis, or septic emboli, among others, with elevated levels of cardiac enzymes, and imaging (ultrasonography, CT scanning, or MRI) of the chest, abdomen, and/or pelvis showing vascular involvement
  • Vascular catheters (arterial, venous): Redness or drainage at insertion site, positive blood culture result (from the catheter and a peripheral site), and catheter tip culture after sterile removal
  • Gastrointestinal:  Colitis, infectious diarrhea, ischemic bowel, or appendicitis, among others, with abdominal pain, distension, diarrhea, and vomiting; positive stool culture result and testing for toxigenic Escherichia coli, Salmonella, Shigella, Campylobacter, or Clostridium difficile
  • Intra-abdominal: Renal abscess, pyelonephritis, pancreatitis, cholecystitis, liver abscess, intra-abdominal abscesses, or perforation, compromise, or rupture of an intra-abdominal or pelvic structure, among others, with specific symptoms and signs4; aerobic and anaerobic culture of drained abdominal fluid collections; peritoneal dialysis (PD) catheter infection with cloudy PD fluid, abdominal pain, deranged cell count, and positive PD fluid culture result
  • Urinary tract:  Cystitis, pyelonephritis, urethritis, or renal abscess, among others, with urgency, dysuria, pelvic, suprapubic, or back pain; urine microscopy showing pyuria or a positive urine culture result; urosepsis has been reported after prostatic biopsy [12]
  • Female genital tract: Pelvic inflammatory disease, cervicitis, or salpingitis, among others, with lower abdominal pain, vaginal discharge, positive results on endocervical and high vaginal swabs
  • Male genital tract: Orchitis, epididymitis, acute prostatitis, balanitis, or prostatic abscess, among others, with dysuria, frequency, urgency, urge incontinence, cloudy urine, prostatic tenderness, and positive urine Gram stain and culture results
  • Bone: Osteomyelitis presenting with pain, warmth, swelling, decreased range of motion, positive blood and/or bone culture results, and MRI changes
  • Joint: Septic arthritis presenting with pain, warmth, swelling, decreased range of motion, positive arthrocentesis with cell counts, and positive Gram stain and culture results
  • Nonspecific systemic febrile syndromes: Babesiosis, rickettsial diseases, lyme disease, typhus, or typhoid fever, among others, with multiorgan involvement, specific travel and epidemiologic exposures, and associated rashes or other symptoms

There are numerous noninfectious causes of fever and organ dysfunction that can mimic sepsis[13] :

  • Alcohol/drug withdrawal
  • Postoperative fever (48 hours postoperatively)
  • Transfusion reaction
  • Drug fever
  • Allergic reaction
  • Cerebral infarction/hemorrhage
  • Adrenal insufficiency/adrenal hemorrhage
  • Myocardial infarction
  • Pancreatitis
  • Acalculous cholecystitis
  • Ischemic bowel
  • Aspiration pneumonitis
  • ARDS (both acute and late fibroproliferative phase)
  • Subarachnoid hemorrhage
  • Fat emboli
  • Transplant rejection
  • Deep venous thrombosis
  • Pulmonary emboli
  • Gout/pseudogout
  • Hematoma
  • Cirrhosis (without primary peritonitis)
  • Gastrointestinal hemorrhage
  • Phlebitis/thrombophlebitis
  • IV contrast reaction
  • Neoplastic fevers
  • Decubitus ulcers

Table 1. Infectious and Noninfectious Causes of Fever [14] (Open Table in a new window)

System

Infectious Causes

Noninfectious Causes

Central nervous

Meningitis, encephalitis

Posterior fossa syndrome, central fever, seizures, cerebral infraction, hemorrhage, cerebrovascular accident

Cardiovascular

Central line, infected pacemaker, endocarditis, sternal osteomyelitis, viral pericarditis, myocardial/perivalvular abscess

Myocardial infarction, balloon pump syndrome, Dressler syndrome

Pulmonary

Ventilator-associated pneumonia, mediastinitis, tracheobronchitis, empyema

Pulmonary emboli, ARDS, atelectasis (without pneumonia), cryptogenic organizing pneumonia, bronchogenic carcinoma without postobstructive pneumonia, systemic lupus erythematosus, pneumonitis, vasculitis

Gastrointestinal

Intra-abdominal abscess, cholangitis, cholecystitis, viral hepatitis, peritonitis, diarrhea (Clostridium difficile)

Pancreatitis, acalculous cholecystitis, ischemia of the bowel/colon, bleeding, cirrhosis, irritable bowel syndrome

Urinary tract

Catheter-associated bacteremia, urosepsis, pyelonephritis, cystitis

Allergic interstitial nephritis

Skin/soft tissue

Decubitus ulcers, cellulitis, wound infection

Vascular ulcers

Bone/joint

Chronic osteomyelitis, septic arthritis

Acute gout

Other

Transient bacteremia, sinusitis

Adrenal insufficiency, phlebitis/thrombophlebitis, neoplastic fever, alcohol/drug withdrawal, delirium tremens, drug fever, fat emboli, deep venous thrombosis, postoperative fever (48 h), fever after transfusion

An abdominal wall abscess is depicted on the CT scan below.

A right lower quadrant abdominal wall abscess and A right lower quadrant abdominal wall abscess and enteric fistula are observed and confirmed by the presence of enteral contrast in the abdominal wall.

Organisms can be introduced via various mechanisms, including direct inoculation of microbes into the body or body site, such as in skin or soft tissue infections or bloodstream infections associated with indwelling venous catheters. Inhalational acquisition is a mode of infection in the setting of respiratory infection, as is aspiration of oral/gastric content. Ascending urinary tract infection can cause systemic infection. The gastrointestinal tract also can be a source of infection if contents macroscopically rupture or seed the intra-abdominal compartment or if organisms translocate through the mucosal barrier. Other mucosal surfaces can serve as entry points, including the conjunctiva, the upper respiratory tract, and the genitourinary tract. External disease-transmitting vectors, such as arthropods, also can cause infection.[6, 15]

The pathophysiology of sepsis is complex and results from the effects of circulating bacterial products, mediated by cytokine release, caused by sustained bacteremia. Cytokines are responsible for the clinically observable effects of bacteremia in the host.[15, 16, 17, 18] Impaired pulmonary, hepatic, or renal function may result from excessive cytokine release during the septic process.

Prognosis

Sepsis is a common cause of mortality and morbidity worldwide. The prognosis depends on underlying health status and host defenses, prompt and adequate surgical drainage of abscesses, relief of any obstruction of the intestinal or urinary tract, and appropriate and early empiric antimicrobial therapy.[19]

The prognosis of sepsis treated in a timely manner and with appropriate therapy is usually good, except in those with intra-abdominal or pelvic abscesses due to organ perforation. When timely and appropriate therapy has been delivered, the underlying physiologic condition of the patient determines outcome.

A systematic review by Winters et al suggested that beyond the standard 28-day in-hospital mortality endpoint, ongoing mortality in patients with sepsis remains elevated up to 2 years and beyond.[20] In addition, survivors consistently demonstrate impaired quality of life.[21]

Clinical characteristics that affect the severity of sepsis and, therefore, the outcome include the host's response to infection, the site and type of infection, and the timing and type of antimicrobial therapy.

Host-related

Abnormal host immune responses may increase susceptibility to severe disease and mortality. For example, extremes of temperature and the presence of leukopenia and/or thrombocytopenia, advanced age, presence of co-morbid conditions, hyperglycemia, bleeding diatheses, and failure of procalcitonin levels to fall are associated with worsened outcome.[22]

Important risk factors for mortality include the patient's comorbidities, functional health status, newly onset atrial fibrillation, hypercoagulability state, hyperglycemia on admission, AIDS, liver disease, cancer, alcohol dependence, and immune suppression.

Age older than 40 years is associated with comorbid illnesses, impaired immunologic responses, malnutrition, increased exposure to potentially resistant pathogens in nursing homes, and increased use of medical devices, such as indwelling catheters and central venous lines.[23, 24, 25, 26]

Infection site

Sepsis due to urinary tract infection has the lowest mortality rate, whereas mortality rates are higher with unknown sources of infection, gastrointestinal sources (highest in ischemic bowel), and pulmonary sources.[27, 28, 29]

Infection type

Sepsis due to nosocomial pathogens has a higher mortality rate than sepsis caused by community-acquired pathogens. Increased mortality is associated with bloodstream infections due to Staphylococcus aureus, fungi, and Pseudomonas, as well as polymicrobial infections. When bloodstream infections become severe (ie, septic shock), the outcome may be similar regardless of whether the pathogenic bacteria are gram-negative or gram-positive.

Antimicrobial therapy

Studies have shown that the early administration of appropriate antibiotic therapy (ie, antibiotics to which the pathogen is sensitive) is beneficial in septic patients demonstrating bacteremia. Previous antibiotic therapy (ie, antibiotics within the prior 90 days) may be associated with increased mortality risk, at least among patients with gram-negative sepsis. Patients who have received prior antibiotic therapy are more likely to have higher rates of antibiotic resistance, reducing the likelihood that appropriate antibiotic therapy will be chosen empirically.[30, 31, 32, 33]

Restoration of perfusion

Failure to attempt aggressive restoration of perfusion early may be associated with an increased mortality risk. A severely elevated lactate level (>4 mmol/L) is associated with a poor prognosis in patients with sepsis.

Epidemiology

Incidence

The incidence of sepsis and the number of sepsis-related deaths are increasing because of an increased use of immunosuppressive medications. The incidence varies by race and sex. The highest incidence is among Black males. The incidence also shows seasonal variation, with the highest number of cases in winter, probably because of the increased prevalence of respiratory infections during this season. Older patients (≥65 years) account for most (60-85%) sepsis cases, attributable to multiple comorbidities and frequent hospitalizations.[19]

Pathogens

The predominant infectious organisms that cause sepsis have changed over the years. Gram-positive bacteria are the most common etiologic pathogens, although the incidence of gram-negative sepsis remains substantial. The incidence of fungal sepsis has been rising with more patients on immunosuppressive therapies and more cases of HIV infection. In approximately half of sepsis cases, the organism is not identified (culture-negative sepsis).

Risk Factors

Risk factors for sepsis and septic shock include the following:

  • ICU admission with subsequent nosocomial infection
  • Bacteremia
  • Advanced age (≥65 years)
  • Immunosuppression - Conditions that impair host defenses such as seen with neoplasms, renal failure, hepatic failure, AIDS, asplenism, diabetes, autoimmune diseases, organ transplant, alcoholism, and the use of immunosuppressant medications and immunomodulators
  • Community-acquired pneumonia
  • Previous hospitalization and antibiotic therapy in the preceding 90 days
  • Genetic factors - Defects of cellular and humoral immunity (low or absent antibody production, T cells, phagocytes, natural killer cells, complement)
  • Urosepsis due to benign prostatic hypertrophy (BPH) in older males or complicated UTI
  • Major trauma and burn injuries
 

Presentation

History

According to Surviving Sepsis Campaign Guidelines 2021, new changes have been made to the guidelines.[1]

 

History and Physical Examination

Nonspecific signs and symptoms

The history and physical examination findings are nonspecific but may suggest the likely source of the septic process and thereby help determine the appropriate antimicrobial therapy and other interventions. General signs and symptoms of sepsis may include the following:

  • Fever, with or without shaking chills (temperature >38.3ºC or < 36ºC)
  • Impaired mental status (in the setting of fever or hypoperfusion)
  • Increased breathing rate (>20 breaths/min) resulting in respiratory alkalosis
  • Warm or cold skin, depending on the adequacy of organ perfusion and dilation of the superficial skin vessels
  • Hypotension requiring pressor agents to maintain systolic blood pressure above 65 mm Hg

Systemic signs and symptoms

The clinical features depicted below may provide important diagnostic clues.

Respiratory infection

Cough, chest pain, and dyspnea may suggest pneumonia or empyema but also may be observed in patients with pulmonary embolism or pleural effusion.

Gastrointestinal (GI) or genitourinary (GU) infection

The patient may have a history of antecedent conditions predisposing to perforation or abscess. In many cases, the history is critical for diagnosis. Abdominal findings on physical examination may be absent or unimpressive.

  • Patients with an intra-abdominal or pelvic source of infection usually have a history of antecedent conditions that predispose to perforation or abscess (eg, chronic or retrocecal subacute appendicitis, diverticulitis, Crohn disease, previous abdominal surgery, or cholecystitis).
  • Diffuse abdominal pain may suggest pancreatitis or generalized peritonitis, whereas right upper abdominal quadrant (RUQ) tenderness may suggest a biliary tract etiology (eg, cholecystitis, cholangitis), and tenderness in the right lower abdominal quadrant (RLQ) suggests appendicitis or Crohn disease. Discrete tenderness over the left lower abdominal quadrant suggests diverticulitis, particularly in elderly patients.
  • A rectal examination may reveal exquisite tenderness caused by a prostatic abscess or, more commonly, an enlarged noninflamed prostate suggestive of prostatitis.
  • A urinary tract source is suggested by an antecedent history of pyelonephritis, stone disease, congenital abnormal collecting system, prostatic hypertrophy, or previous operations or procedures involving the prostate or kidneys. [34, 35] Costovertebral angle tenderness with a fever suggests acute pyelonephritis. Subacute or chronic pyelonephritis may manifest as only mild tenderness.

Intravenous line infection

Evidence of infection at a central IV line site suggests the probable etiology.[36] However, it is important to note that many patients with central IV line infections do not have superficial evidence of infection at the insertion site. Always suspect IV line infections, especially when other sources of sepsis are eliminated.[37, 38] Central IV lines are the lines most commonly associated with bacteremia or sepsis.

Peripheral venous lines and arterial lines are rarely associated with bacteremia. Thrombophlebitis may be noted at the peripheral IV line site.

Surgical wound infection

Pain, purulent exudate, or crepitus in a surgical wound may suggest wound infection, cellulitis, or abscess.

Signs of end-organ hypoperfusion

These signs include the following:

  • Warm, flushed skin may be present in the early phases of sepsis. The skin may become cool and clammy with progression to shock due to redirection of blood flow to core organs. Decreased capillary refill, purpura cyanosis, or mottling may be seen.
  • Altered mental status, obtundation, restlessness
  • Oliguria or anuria due to hypoperfusion
  • Ileus or absent bowel sounds

Special considerations

Elderly patients may present with peritonitis and may not experience rebound tenderness of the abdomen.[39]

Elderly individuals, persons with diabetes, and patients on beta-blockers may not exhibit an appropriate tachycardia as blood pressure falls.

Younger patients develop a severe and prolonged tachycardia without hypotension until acute decompensation occurs.

Patients with chronic hypertension may develop critical hypoperfusion at a blood pressure that is higher than in healthy patients (ie, relative hypotension).

An acute surgical abdomen in a pregnant patient may be difficult to diagnose.[40] The most common cause of sepsis in pregnancy is urosepsis.[40]

Physical Examination

The physical examination may vary according to the organ system involved and the infectious versus noninfectious etiology of sepsis. 

Complications

The most dire complication of sepsis is the high rate of morbidity and mortality associated with it especially if it is not identified in a timely manner and resuscitative measures including IV fluids, pressors, IV antibiotics, or specific therapies are not initiated urgently or emergently.

 

DDx

Diagnostic Considerations

Sepsis often is associated with or preceded by other conditions (see Table 2 below).[41, 42, 43] Noninfectious conditions that present in a manner similar to that of sepsis must also be considered, as should the host's immunocompetence. Early diagnosis with rapid initiation of appropriate therapy is the cornerstone of reducing mortality and morbidity associated with sepsis. Diagnostic studies should be sent within the first 3 hours of suspected sepsis, and antibiotics should be initiated within the first 45 minutes after appropriate cultures are collected. If the blood pressure remains less than 65 mm Hg despite initial fluid resuscitation of 30 mL/kg or if the initial lactate level is 4 mmol/L (36 mg/dl) or higher within 6 hours, further hemodynamic assessments should be performed to ensure adequate organ perfusion. It is essential to reach a preliminary diagnosis within the first 12 hours of presentation to decrease the likelihood of adverse clinical outcomes.

Table 2. Clinical Conditions Associated With Sepsis (Open Table in a new window)

System 

Associated With Sepsis

Not Typically Associated With Sepsis 

GI tract

Liver

Gallbladder

Colon

Abscess

Intestinal obstruction

Instrumentation

Esophagitis

Gastritis

Pancreatitis (may have multiorgan dysfunction but not infectious in origin)

Small bowel disorders

GI bleeding

GU tract 

Pyelonephritis

Intra- or perinephric abscess

Renal calculi

Urinary tract obstruction

Acute prostatitis/abscess

Renal insufficiency

Instrumentation in patients with bacteriuria

Urethritis

Cystitis

Cervicitis

Vaginitis

Catheter-associated bacteriuria (in otherwise healthy hosts without genitourinary tract disease)

Pelvis

Peritonitis

Abscess

 

 

Upper respiratory tract

Deep neck space infection

Abscess

Pharyngitis

Sinusitis

Bronchitis

Otitis

Lower respiratory tract

Community-acquired pneumonia (with asplenia)

Empyema

Lung abscess

Community-acquired pneumonia (in otherwise healthy host)

 

 

 

Intravascular

IV line sepsis

Infected prosthetic device

Acute bacterial endocarditis

 

Cardiovascular

Acute bacterial endocarditis

Myocardial/perivalvular ring abscess

Subacute bacterial endocarditis

 

CNS

Bacterial meningitis

Aseptic meningitis

Skin/soft-tissue

 

Necrotizing fasciitis

 

Osteomyelitis

Uncomplicated wound infections

CNS = central nervous system; GI = gastrointestinal; GU = genitourinary; IV = intravenous. Adapted from: Cunha BA, Shea KW. Fever in the intensive care unit. Infect Dis Clin North Am. Mar 1996;10(1):185-209.[41]

Pseudosepsis

A common medicolegal error is failure to consider pseudosepsis as a cause of the presenting syndrome. Most causes of pseudosepsis are readily treatable if recognized and managed early.

Thus, before embarking on a workup for sepsis or beginning empiric antibiotic therapy, it is vital to rule out the treatable causes of pseudosepsis early in the disease process. Consider other causes or conditions that mimic the clinical and hemodynamic parameters of sepsis and differentiate between the distributive presentation versus septic shock (see Table 3 below). The causes of pseudosepsis must be identified because they require supportive, rather than antimicrobial, therapy.

Table 3. Noninfectious Conditions Mimicking Clinical and Hemodynamic Parameters of Sepsis (Open Table in a new window)

Clinical Presentations Mimicking Sepsis

Hemodynamic Parameters Mimicking Sepsis

Myocardial infarction

Spinal cord injury

Pancreatitis

Adrenal insufficiency

Diabetic ketoacidosis

Acute pancreatitis

Systemic lupus erythematosus flare with abdominal crisis

Hemorrhage

Ventricular pseudoaneurysm

Pulmonary embolism

Massive aspiration/atelectasis

Anaphylaxis

Systemic vasculitis

 

Hypovolemia (eg, due to diuretics, dehydration)

 

Pseudosepsis is a common cause of misdiagnosis in hospitalized patients, particularly in the emergency department (ED) and ICU. The most common causes of pseudosepsis include gastrointestinal (GI) hemorrhage, pulmonary embolism, acute myocardial infarction (MI), acute pancreatitis (edematous or hemorrhagic), diuretic-induced hypovolemia, and relative adrenal insufficiency.

Patients with pseudosepsis may have fever, chills, leukocytosis, and a left shift, with or without hypotension. Many causes of pseudosepsis produce pulmonary artery catheter readings that are compatible with sepsis (ie, increased cardiac output and decreased peripheral resistance), which could misdirect the unwary clinician (see Table 4 below).

Table 4. Characteristics of Pseudosepsis and Sepsis (Open Table in a new window)

Parameters

Pseudosepsis

Sepsis

Microbiologic

No definite source PLUS ≥1 abnormalities

Negative blood cultures excluding contaminants

Proper identification/process/source PLUS ≥1 microbiologic abnormalities

Positive buffy coat smear result OR several positive blood culture results with a pathogenic organism

Hemodynamic

⇓ PVR

⇑ CO

⇓ PVR

⇑ CO

Left ventricular dilatation

Laboratory

⇑ WBC count (with left shift)

Normal platelet count

⇑ FSP

⇑ Lactate

⇑ D-dimers

⇑ PT/PTT

⇓ Albumin

⇓ Fibrinogen

⇓ Globulins

⇑ WBC count (with left shift)

⇓ Platelets

⇑ FSP

⇑ Lactate

⇑ D-dimers

⇑ PT/PTT

⇓ Albumin

Clinical

≤102°F ±

Tachycardia ±

Respiratory alkalosis ±

Hypotension

≥102°F OR

Hypothermia ±

Mental status changes ±

Hypotension

CO = cardiac output; FSP = fibrin split products; GI = gastrointestinal; GU = genitourinary; PT/PTT = prothrombin time/partial thromboplastin time; PVR = peripheral vascular resistance; WBC = white blood cell.

Host immunocompetence

Otherwise healthy hosts with community-acquired pneumonia virtually never present with hypotension or sepsis; however, patients with decreased or absent splenic function may present with overwhelming pneumococcal sepsis. If an otherwise healthy patient with community-acquired pneumonia presents with shock and all of the other causes of pseudosepsis are ruled out, then it must be assumed that the patient is a compromised host with impaired or absent splenic function.

Differential Diagnoses

 

Workup

Approach Considerations

Multiple clinical, laboratory, radiologic, and microbiologic data are required for the diagnosis of sepsis and septic shock. Sepsis should never be diagnosed based on a single abnormality. However, the diagnosis is often made empirically at the bedside upon presentation or retrospectively when follow-up data return (eg, positive blood culture result) or a response to antibiotics is evident. Importantly, the identification of a pathogenic organism, although preferred, is not always feasible since the responsible organism may be unidentified in many patients.

In general, the workup for sepsis may include the following:

  • Blood culture and urine analysis and culture
  • Chemistry studies that can suggest organ dysfunction, such as liver or kidney function tests
  • Serum lactate levels obtained urgently and serially.
  • Chest radiology
  • Diagnostic imaging of the chest and abdomen/pelvis
  • Cardiac studies such as ECG and troponins, as indicated
  • Interventions such as paracentesis, thoracentesis, lumbar puncture, or aspiration of an abscess, as clinically indicated
  • Measurement of biomarkers of sepsis such as procalcitonin levels

Laboratory Studies

Complete blood cell count

A complete blood cell (CBC) count is usually not specific. Leukocytosis with a left shift is also a nonspecific diagnostic finding and can be seen in noninfectious conditions. Leukopenia, anemia, and thrombocytopenia may be observed in sepsis.

Complete metabolic profile

A complete metabolic profile identifies changes in organ function, especially the liver and kidneys.

Bacterial cultures

Obtain blood cultures in all patients upon admission. Negative blood culture results are also necessary to include pseudosepsis in the differential diagnosis.[44] Blood culture isolates might suggest the underlying disease process. Bacteroides fragilis suggests a colonic or pelvic source, whereas Klebsiella species or enterococci suggest a gallbladder or urinary tract source.

If central intravenous (IV) line sepsis is suspected, remove the line and send the tip for semiquantitative bacterial culture. If culture of the catheter tip yields positive results and demonstrates 15 or more colonies and if the isolate from the tip matches the isolate from the blood culture, an infection associated with the central IV line is diagnosed.

ICU patients are at a greater risk for colonization by MRSA, vancomycin-resistant enterococci (VRE), and carbapenem-resistant Enterobacteriaceae (CRE). It is critical to deescalate or change the empiric antibiotic regimen once the organism susceptibilities are available.

Gram staining

Buffy coat analysis of CBC may be useful in identifying certain infectious agents, although the yield is low.[45]

Urinalysis with reflex to culture

If urosepsis is suspected, obtain a urine Gram stain, urinalysis, and urine culture. A systematic review found that in adult ICU patients, catheter-associated urinary tract infection was associated with significantly higher mortality and a longer stay.[46]

Microbiology

Organism identification via culture in a patient who fulfills the definition of sepsis is highly supportive of a sepsis diagnosis but is unnecessary. The rationale behind its lack of inclusion in the diagnostic criteria for sepsis is that a culprit organism goes unidentified in up to half of patients who present with sepsis, and a positive culture result is not required to make a decision regarding treatment with empiric antibiotics.

Unique laboratory findings

Laboratory and clinical features that may suggest an underlying etiology of sepsis are as follows:

  • Leukocytosis (WBC count >12,000/µL) or leukopenia (WBC count < 4000/µL)
  • Normal WBC count with greater than 10% immature forms (left shift with bandemia)
  • Hyperglycemia (plasma glucose level >140 mg/dL or 7.7 mmol/L) in the absence of diabetes [25]
  • Plasma C-reactive protein level of more than 2 standard deviations above the reference value
  • Arterial hypoxemia (PaO 2/FiO 2 ratio < 300 mm Hg)
  • Acute oliguria (urine output < 0.5 mL/kg/hour for at least 2 hours despite adequate fluid resuscitation)
  • Creatinine increase >0.5 mg/dL or 44.2 mmol/L
  • Coagulation abnormalities (INR >1.5 or PTT >60 seconds)
  • Thrombocytopenia (platelet count < 100,000/µL) [24]
  • Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L)
  • Adrenal insufficiency (eg, hyponatremia, hyperkalemia) and euthyroid sick syndrome can also be found in sepsis.
  • Hyperlactatemia (serum lactate >2 mmol/L) can result from organ hypoperfusion in the presence or absence of hypotension and indicates a poor prognosis. A serum lactate level of 4 mmol/L or more (especially arterial lactate) indicates septic shock.
  • Plasma procalcitonin and presepsin elevation is associated with bacterial infection and sepsis. [7, 8, 9, 10]

Procalcitonin levels

Procalcitonin (PCT) is an acute-phase reactant that is elevated in severe bacterial infections. In most clinical assays, the reference range of PCT is below detectable. Measurement of PCT and C-reactive protein (CRP) at onset and on the fourth day of treatment can predict survival of patients with ventilator-associated pneumonia. A decrease in either one of these marker values predicts survival.[9]

A study from van Nieuwkoop et al examined the use of PCT levels in predicting bacteremia in a group of 581 patients, 136 of whom had bacteremia; PCT levels successfully identified 94-99% of the patients with bacteremia.[7]

Heyland et al, in a systematic review of the economic value of PCT-guided reduction in antibiotic use in intensive care, found that with hospital mortality and length of stay unchanged, PCT testing to reduce antibiotic treatment broke even when daily antibiotics cost about $150 in Canadian dollars.[8]

Chest Radiology and Chest CT Scan

Chest Radiography

No radiologic signs are specific to the identification of sepsis, but chest radiography can aid in identifying a specific infection site. Chest radiography is important to rule out pneumonia and diagnose other causes of pulmonary infiltrates, such as the following:

  • Pulmonary drug reactions
  • Pulmonary embolism
  • Pulmonary hemorrhage
  • Primary or metastatic pulmonary neoplasms
  • Lymphangitic spread of malignancies
  • Large pleural effusions
  • Pneumothorax
  • Hydrothorax
  • Fluid overload
  • Congestive heart failure (CHF)
  • Acute myocardial infarction (MI)
  • Acute respiratory distress syndrome

Chest CT Scanning

Chest CT scanning is a very sensitive modality for diagnosing the lung pathology listed above.

Abdominal Ultrasonography, CT Scanning, and MRI

Perform abdominal ultrasonography if biliary tract obstruction is suspected based on the clinical presentation. However, abdominal ultrasonography is suboptimal for the detection of abscesses or perforated hollow organs. Ultrasonograms in patients with cholecystitis may show a thickened gallbladder wall or biliary calculi but no dilatation of the common bile duct (CBD). Stones in the biliary tract may or may not be visible in patients with cholangitis, but the CBD typically is dilated.[47]

Use computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen if a nonbiliary intra-abdominal source of infection is suspected on the basis of the history or physical examination findings. Abdominal CT or MRI is also helpful in delineating intrarenal and extrarenal pathology. Gallium or indium scanning has no place in the initial workup of sepsis; patients with sepsis are acutely ill by definition, and rapid diagnostic tests (eg, CT or MRI of the abdomen and ultrasonography of the right upper quadrant) are time-critical, life-saving tools. However, MRI is more time consuming than CT scanning, and the latter is preferred in emergent situations.[47]

Cardiac Studies

If acute MI is likely, perform electrocardiography (ECG) and obtain cardiac enzyme levels. Remember that certain patients may present with a silent, asymptomatic MI, which should be included in the differential diagnosis of otherwise unexplained fever, leukocytosis, and hypotension. Silent MIs are common in elderly patients and in those who have recently undergone abdominal or pelvic surgical procedures. They are also common in individuals with alcoholism, diabetes, and uremic conditions.

The following cardiac studies may be useful if cardiac involvement or disease is suspected as a cause or complication of infection:

  • Electrocardiography (ECG) to evaluate for conduction abnormalities or delays or arrhythmias
  • Cardiac enzyme levels
  • Echocardiography to evaluate for structural heart disease

Invasive Interventions

Invasive diagnostic procedures that may be considered are discussed below.

Thoracentesis/paracentesis

Perform thoracentesis for diagnostic purposes in patients with substantial pleural effusion. Perform paracentesis in patients with gross ascites.

Surgical incision and drainage

Drainage of fluid collections/abscesses is crucial in establishing good source control and in facilitating a good clinical response to subsequent antibiotic therapy.

Bronchoscopy

Bronchoscopy with washing, lavage, or other invasive sampling is performed in patients with suspected pneumonia and in patients with suspected invasive fungal infections of the lung.

Swan-Ganz catheterization

In highly selected cases, a Swan-Ganz catheter may be useful in managing the fluid status of the patient and in assessing left ventricular dysfunction; however, routine use is not recommended.

Imaging Studies

Site-specific soft tissue imaging includes ultrasonography, CT scanning, or MRI to assess for possible abscess, fluid collection, or necrotizing skin infection. These are essential for diagnostic purposes and for monitoring the response to therapy.

Contrast-enhanced CT scanning or MRI of the brain/neck is performed to assess for possible masses, abscess, fluid collection, or necrotizing infection.

 

Treatment

Approach Considerations

Early aggressive medical therapy is indicated in patients with suspected sepsis.[30, 31, 48, 49, 50, 51, 52, 53, 54, 55]

Sepsis Treatment

Patients with sepsis are generally ill and require inpatient hospitalization or admission to the intensive care unit (ICU) for monitoring and treatment. Admission to an ICU depends on the severity of the septic process and the degree of organ dysfunction. In July 2018, the US Centers for Medicare and Medicaid Services (CMS) began public reporting of a national sepsis bundle quality measure, commonly referred to as SEP-1. Early data demonstrated that only half of sepsis patients nationally received the full CMS-recommended bundle for emergency and hospital care. The treatment guidelines have been revised by IDSA/ Emergency Medicine Collaborative Task Force[56]  and Surviving Sepsis Campaign Guidelines 2021.[1]

Determine the likely source of the infection, and administer intravenous (IV) empiric antimicrobial agents until culture results become available, at which point more narrow-spectrum agents can be used (see below). In addition, offer supportive therapy aimed at maintaining organ perfusion, and provide respiratory support when necessary.[50, 57, 58]

A recent prospective study of 5787 adult patients with severe sepsis revealed the importance of goal-directed treatment. Patients triaged and managed according to 4 clinical goals (blood cultures before antibiotics, lactate before 90 minutes, IV antibiotics before 180 minutes, and 30 mL/kg of IV fluids before 180 minutes) were significantly less likely to die in the hospital than were those for whom all 4 of these goals were not met (22.6% vs 26.5%, respectively).[59]

In a multivariate regression analysis adjusted for age, admission to the intensive care unit (ICU), vasopressor initiation, central venous catheter insertion, and monitoring of central venous pressure and central venous oxygen saturation, complete compliance with the clinical goals was associated with a survival odds ratio of 1.194 (1.04-1.37).[59]

Surgical Intervention

Early evaluation in patients with presumed intra-abdominal or pelvic sepsis is essential, and surgical consultation should be obtained in appropriate patients.

Consultations

Obtain a consultation with a surgeon for patients with presumed intra-abdominal or pelvic sepsis. Obtain a consultation with an infectious disease specialist, as indicated, in patients with presumed or proven sepsis.[30]

Antimicrobial Therapy

Appropriate antimicrobial therapy depends on adequate coverage of the bacteria associated with the specific organ or organ system associated with the infection.[30, 31, 32, 48, 49]  Agents suitable for empiric monotherapy regimens (depending on the source and underlying microbiology of the sepsis because the agent must be able to cover all of the likely pathogens) may include the following:

  • Imipenem
  • Meropenem
  • Tigecycline
  • Piperacillin-tazobactam
  • Ampicillin-sulbactam
  • Moxifloxacin

Combination therapeutic regimens include metronidazole plus either levofloxacin, aztreonam, a third- or fourth-generation cephalosporin, or an aminoglycoside.

Many advocate also using antistaphylococcal coverage (eg, vancomycin) empirically.

Although no drug regimen may be superior to another, time to first dose administration is very important. Mortality data suggest that early administration of appropriate antibiotics is correlated with better survival. Alternative agents may be used alone or in combination, with a good adverse-effect profile.[30, 31, 48, 49]

Antibiotics are normally continued until the septic process and surgical interventions have controlled the source of infection. Ordinarily, patients are treated for approximately 2 weeks, although duration may vary according to the source, site, and severity of the infection. As soon as patients are able to tolerate medications orally, they may be switched to an equivalent oral antibiotic regimen in an IV-to-oral conversion program.

Empiric therapy for IV line infections

A detailed discussion of catheter-associated infections is available in the IDSA catheter-associated line-related infections (CRBSI) guidelines.[60] IV line infections most often are due to Staphylococcus aureus (methicillin-sensitive S aureus [MSSA] or methicillin-resistant S aureus [MRSA]), but gram-negative bacilli can be involved. The preferred empiric therapy for these infections is meropenem or cefepime (for Pseudomonas) plus additional coverage for staphylococci.[37, 38] If MRSA is prevalent in the institution, add linezolid, vancomycin, or daptomycin. Otherwise, nafcillin, oxacillin, or cefazolin provide adequate coverage for MSSA.

Unless coagulase-negative, methicillin-sensitive staphylococci are recovered from the blood, with high-level bacteremia (3 or 4 positive blood cultures out of 4), avoid vancomycin for empiric therapy if possible; these are low-virulence organisms and may represent contaminants. If treatment is advised, the duration of therapy depends on the severity and site of infection.[60]

Treatment of staphylococcal central line infection and fungal or gram-negative organisms typically requires removal of the line.

Minimize the use of vancomycin in order to prevent the emergence of vancomycin-resistant enterococci (VRE).[37]

Empiric therapy for biliary tract infections

IDSA guidelines for complicated intra-abdominal infections such as biliary tract infections are available.[61] The main biliary tract pathogens include Escherichia coli, Klebsiella species, and Enterococcus faecalis. Coverage for staphylococci is not needed in the biliary tract. Anaerobes can also be important, especially in patients with diabetes or immunosuppression.

Preferred monotherapy regimens for biliary tract infections include imipenem, meropenem, ampicillin-sulbactam, or piperacillin-tazobactam. Cephalosporins or quinolones in combination with metronidazole are alternate first-line agents for the treatment of biliary tract infections.

Empiric therapy for intra-abdominal and pelvic infections

The main pathogens in the lower abdomen and pelvis include aerobic coliform gram-negative bacilli and B fragilis. Enterococci do not require special coverage unless the patient has recurrent infection or enterococci have been specifically and repeatedly isolated. Potent anti–B fragilis and aerobic gram-negative bacillary coverage are essential, in addition to surgical intervention when drainage or repair of intra-abdominal viscera is required.

Preferred monotherapy regimens for intra-abdominal and pelvic infections include imipenem, meropenem, piperacillin-tazobactam, ampicillin-sulbactam, or tigecycline. Alternate combination therapy for intra-abdominal and pelvic infections consists of clindamycin or metronidazole plus a third- or fourth-generation cephalosporin, aztreonam, levofloxacin, or an aminoglycoside. Some authors raise concerns about the use of tigecycline.

Empiric therapy for urosepsis

The primary uropathogens include gram-negative aerobic bacilli, such as coliforms or enterococci. Pseudomonas aeruginosa, Enterobacter species, and Serratia species are rare uropathogens and are associated with urologic instrumentation.

Monotherapy for urosepsis due to aerobic gram-negative bacilli may include aztreonam, levofloxacin, a third- or fourth-generation cephalosporin, or an aminoglycoside. However, preferred monotherapy for enterococcal urosepsis involves ampicillin or vancomycin. For VRE urosepsis, linezolid or daptomycin may be used.

Empiric therapy for community-acquired urosepsis consists of levofloxacin, aztreonam, or an aminoglycoside plus ampicillin. For nosocomial urosepsis, a fourth-generation cephalosporin, piperacillin-tazobactam, imipenem, or meropenem, with or without an aminoglycoside, is preferred.

Empiric therapy for staphylococcal, pneumococcal, and meningococcal sepsis

S aureus sepsis is usually associated with infection caused by devices or bacterial endocarditis. Empiric therapy may be with an anti-staphylococcal penicillin (nafcillin or oxacillin), vancomycin, a cephalosporin, daptomycin, or linezolid, depending on the concern for MRSA.

Pneumococcal or meningococcal sepsis may be treated with penicillin G or a beta-lactam. In patients with associated meningococcal meningitis, the antibiotic selected should penetrate the cerebrospinal fluid (CSF) and should be given in meningeal doses. Consider the regional prevalence of drug-resistant pneumococci when selecting an antibiotic.

Empiric therapy for sepsis of unknown origin

The usual sources of sepsis are the distal gastrointestinal (GI) tract, the pelvis, and the genitourinary (GU) tract. Organisms that should be covered from these areas include aerobic gram-negative bacilli (coliforms) and B fragilis. Enterococci are important pathogens in biliary tract sepsis and urosepsis.

Preferred empiric monotherapy includes meropenem, imipenem, piperacillin-tazobactam, or tigecycline.

Empiric combination therapy includes metronidazole plus levofloxacin, aztreonam, or a third- or fourth-generation cephalosporin.

Outpatient management

If orally administered antibiotics are continued at home, advise the patient about possible adverse effects. If additional antimicrobial therapy is needed outside the hospital setting, it should be given orally, not intravenously. Do not allow the total course of antibiotics to exceed 3 weeks, except for specific clinical scenarios, which may require prolonged courses of oral antibiotics for cure or complete clinical resolution.

 

Guidelines

Guidelines Summary

The initial sepsis guidelines were published in 2004 and then revised in 2008 and 2012. The 2016 clinical practice guidelines are a revision of the 2012 Surviving Sepsis Campaign (SSC) guidelines for the management of severe sepsis and septic shock. The latest guidelines were 2021 Surviving Sepsis Campaign Guidelines that were revised by IDSA/ Emergency Medicine Collaborative Task Force [56] and Surviving Sepsis Campaign Guidelines 2021.[1]

Major New Recommendations in the 2012 Update

Emphasis was directed to (1) first-hour fluid resuscitation and inotrope therapy directed to goals of threshold heart rates, normal blood pressure, and capillary refill of 2 seconds or less with specific evaluation after each bolus for signs of fluid overload, as well as first-hour antibiotic administration and (2) subsequent ICU hemodynamic support directed to goals of ScVO2 greater than 70% and cardiac index (CI) 3.3-6 L/min/m2 with appropriate antibiotic coverage and source control.[62]

Another major new recommendation in the 2012 update was that hemodynamic support of septic shock should be addressed at the institutional level rather than only at the practitioner level, with well-planned coordination between the family, community, prehospital, emergency department, hospital, and ICU settings. The 2012 guidelines recommend that each institution implement their own adopted or home-grown bundles that include the following:

  • Recognition bundle containing a trigger tool for rapid identification of patients with suspected septic shock at that institution
  • Resuscitation and stabilization bundle to drive adherence to consensus best practice at that institution
  • Performance bundle to monitor, improve, and sustain adherence to that best practice

The 2016 Surviving Sepsis Campaign Guidelines

The 2016 guidelines[63, 64] give a detailed overview of initial resuscitation, screening, and diagnosis of sepsis. The management decisions concerning antibiotic therapy, fluid administration, source control, administration of pressors and steroids, blood products, anticoagulants, immunoglobulins, mechanical ventilation, sedation, analgesia, glucose control, blood purification, renal replacement therapy, bicarbonate, venous thromboembolism and stress ulcer prophylaxis, nutrition, and setting goals of care are addressed. The main differences between the 2012 and 2016 guidelines are discussed in detail in the cited reference.[65]

Unfortunately, a consensus could not be reached between some of the sponsoring organizations. A position paper issued by the IDSA does not endorse the Society of Critical Care Medicine/European Society of Intensive Care Medicine (SCCM/ESICM) 2016 Surviving Sepsis Campaign guidelines for the management of sepsis and septic shock, despite the IDSA's participation in the development of the guidelines. In particular, while the IDSA agrees that the SCCM/ESICM recommendations are life-saving for patients with septic shock, they may lead to overtreatment in those with milder variants of sepsis and sepsis syndromes. The IDSA does not endorse routine initiation of antibiotic therapy within one hour of suspecting sepsis nor administration of combination antibiotic therapy and a 7- to 10-day course of antibiotic therapy for all patients, regardless of presentation factors. The IDSA also notes unclear recommendations for removal of catheters when considered as the source of sepsis and for the role of procalcitonin when monitoring therapeutic response.[66]

As more research related to timing of therapy is completed, further guideline refinement is expected, and perhaps a consensus regarding the treatment approach can be achieved.

The 2021 Surviving Sepsis Campaign Guidelines

In 2021 after the Covid pandemic the guidelines for Sepsis have been changed significantly in terms of sepsis screening, diagnosis with qSOFA vs NEWS, MEWS or SIRS criteria, use of antibiotics, resuscitation including pressor support, IV fluids and use of steroids and blood purification techniques. Following is a tabulated list of changes from prior guidelines for a quick reference. 

Table 1. Table of Current Recommendations and Changes From Previous 2016 Recommendations [1] (Open Table in a new window)

Recommendations 2021 Recommendation Strength and Quality of Evidence Changes From 2016 Recommendations
1. For hospitals and health systems, we recommend using a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients and standard operating procedures for treatment. Strong; moderate-quality evidence (for screening) Changed from Best practice statement
“We recommend that hospitals and hospital systems have a performance improvement program for sepsis including sepsis screening for acutely ill, high-risk patients.”
Strong; very low-quality evidence (for standard operating procedures)
2. We recommend against using qSOFA compared with SIRS, NEWS, or MEWS as a single-screening tool for sepsis or septic shock. Strong; moderate-quality evidence NEW
3. For adults suspected of having sepsis, we suggest measuring blood lactate. Weak; low quality of evidence  
INITIAL RESUSCITATION    
4. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately. Best practice statement  
5. For patients with sepsis induced hypoperfusion or septic shock we suggest that at least 30 mL/kg of IV crystalloid fluid should be given within the first 3 hr of resuscitation. Weak; low quality of evidence DOWNGRADE from Strong; low quality of evidence
“We recommend that in the initial resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 hr”
6. For adults with sepsis or septic shock, we suggest using dynamic measures to guide fluid resuscitation, over physical examination or static parameters alone. Weak; very low quality of evidence  
7. For adults with sepsis or septic shock, we suggest guiding resuscitation to decrease serum lactate in patients with elevated lactate level, over not using serum lactate. Weak; low quality of evidence  
8. For adults with septic shock, we suggest using capillary refill time to guide resuscitation as an adjunct to other measures of perfusion. Weak; low quality of evidence NEW
MEAN ARTERIAL PRESSURE    
9. For adults with septic shock on vasopressors, we recommend an initial target mean arterial pressure (MAP) of 65 mm Hg over higher MAP targets. Strong; moderate-quality evidence  
ADMISSION TO INTENSIVE CARE    
10. For adults with sepsis or septic shock who require ICU admission, we suggest admitting the patients to the ICU within 6 hr. Weak; low quality of evidence  
INFECTION    
11. For adults with suspected sepsis or septic shock but unconfirmed infection, we recommend continuously re-evaluating and searching for alternative diagnoses and discontinuing empiric antimicrobials if an alternative cause of illness is demonstrated or strongly suspected. Best practice statement  
12. For adults with possible septic shock or a high likelihood for sepsis, we recommend administering antimicrobials immediately, ideally within 1 hr of recognition. Strong; low quality of evidence (Septic shock) CHANGED from previous: “We recommend that administration of intravenous antimicrobials should be initiated as soon as possible after recognition and within one hour for both a) septic shock and b) sepsis without shock”
Strong; very low quality of evidence (Sepsis without shock)
Strong recommendation; moderate quality of evidence
13. For adults with possible sepsis without shock, we recommend rapid assessment of the likelihood of infectious versus noninfectious causes of acute illness. Best practice statement  
14. For adults with possible sepsis without shock, we suggest a time-limited course of rapid investigation and if concern for infection persists, the administration of antimicrobials within 3 hr from the time when sepsis was first recognized. Weak; very low quality of evidence NEW from previous:
“We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within 1 hr for both a) septic shock and b) sepsis without shock”
Strong recommendation; moderate quality of evidence
15. For adults with a low likelihood of infection and without shock, we suggest deferring antimicrobials while continuing to closely monitor the patient. Weak; very low quality of evidence NEW from previous:
“We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within 1 hr for both a) septic shock and b) sepsis without shock“
Strong recommendation; moderate quality of evidence
16. For adults with suspected sepsis or septic shock, we suggest against using procalcitonin plus clinical evaluation to decide when to start antimicrobials, as compared with clinical evaluation alone. Weak; very low quality of evidence  
17. For adults with sepsis or septic shock at high risk for MRSA, we recommend using empiric antimicrobials with MRSA coverage over using antimicrobials without MRSA coverage. Best practice statement NEW from previous:
“We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.”
Strong recommendation; moderate quality of evidence
18. For adults with sepsis or septic shock at low risk for MRSA, we suggest against using empiric antimicrobials with MRSA coverage, as compared with using antimicrobials without MRSA coverage. Weak; low quality of evidence NEW from previous:
“We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.”
Strong recommendation; moderate quality of evidence
19. For adults with sepsis or septic shock and high risk for multidrug resistant (MDR) organisms, we suggest using two antimicrobials with gram-negative coverage for empiric treatment over one gram-negative agent. Weak; very low quality of evidence  
20. For adults with sepsis or septic shock and low risk for multidrug resistant (MDR) organisms, we suggest against using two gram-negative agents for empiric treatment, as compared to one gram-negative agent. Weak; very low quality of evidence  
21. For adults with sepsis or septic shock, we suggest against using double gram-negative coverage once the causative pathogen and the susceptibilities are known. Weak; very low quality of evidence  
22. For adults with sepsis or septic shock at high risk for fungal infection, we suggest using empiric antifungal therapy over no antifungal therapy. Weak; low quality of evidence NEW from previous:
“We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.”
Strong recommendation; moderate quality of evidence
23. For adults with sepsis or septic shock at low risk of fungal infection, we suggest against empiric use of antifungal therapy Weak; low quality of evidence NEW from previous:
“We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.“
Strong recommendation; moderate quality of evidence
24. We make no recommendation on the use of antiviral agents. No recommendation  
25. For adults with sepsis or septic shock, we suggest using prolonged infusion of beta-lactams for maintenance (after an initial bolus) over conventional bolus infusion. Weak; moderate-quality evidence  
26. For adults with sepsis or septic shock, we recommend optimising dosing strategies of antimicrobials based on accepted pharmacokinetic/pharmacodynamic (PK/PD) principles and specific drug properties. Best practice statement  
27. For adults with sepsis or septic shock, we recommend rapidly identifying or excluding a specific anatomical diagnosis of infection that requires emergent source control and implementing any required source control intervention as soon as medically and logistically practical. Best practice statement  
28. For adults with sepsis or septic shock, we recommend prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established. Best practice statement  
29. For adults with sepsis or septic shock, we suggest daily assessment for de-escalation of antimicrobials over using fixed durations of therapy without daily reassessment for de-escalation. Weak; very low quality of evidence  
30. For adults with an initial diagnosis of sepsis or septic shock and adequate source control, we suggest using shorter over longer duration of antimicrobial therapy. Weak; very low quality of evidence  
31. For adults with an initial diagnosis of sepsis or septic shock and adequate source control where optimal duration of therapy is unclear, we suggest using procalcitonin AND clinical evaluation to decide when to discontinue antimicrobials over clinical evaluation alone. Weak; low quality of evidence  
HEMODYNAMIC MANAGEMENT    
32. For adults with sepsis or septic shock, we recommend using crystalloids as first-line fluid for resuscitation. Strong; moderate-quality evidence  
33. For adults with sepsis or septic shock, we suggest using balanced crystalloids instead of normal saline for resuscitation. Weak; low quality of evidence CHANGED from weak recommendation; low quality of evidence.
“We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock”
34. For adults with sepsis or septic shock, we suggest using albumin in patients who received large volumes of crystalloids. Weak; moderate-quality evidence  
35. For adults with sepsis or septic shock, we recommend against using starches for resuscitation. Strong; high-quality evidence  
36. For adults with sepsis and septic shock, we suggest against using gelatin for resuscitation. Weak; moderate-quality evidence UPGRADE from weak recommendation; low quality of evidence
“We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock.”
37. For adults with septic shock, we recommend using norepinephrine as the first-line agent over other vasopressors. Strong  
Dopamine. High-quality evidence
Vasopressin. Moderate-quality evidence
Epinephrine. Low quality of evidence
Selepressin. Low quality of evidence
Angiotensin II. Very low-quality evidence
38. For adults with septic shock on norepinephrine with inadequate mean arterial pressure levels, we suggest adding vasopressin instead of escalating the dose of norepinephrine. Weak; moderate quality evidence  
39. For adults with septic shock and inadequate mean arterial pressure levels despite norepinephrine and vasopressin, we suggest adding epinephrine. Weak; low quality of evidence  
40. For adults with septic shock, we suggest against using terlipressin. Weak; low quality of evidence  
41. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we suggest either adding dobutamine to norepinephrine or using epinephrine alone. Weak; low quality of evidence  
42. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we suggest against using levosimendan. Weak; low quality of evidence NEW
43. For adults with septic shock, we suggest invasive monitoring of arterial blood pressure over noninvasive monitoring, as soon as practical and if resources are available. Weak; very low quality of evidence  
44. For adults with septic shock, we suggest starting vasopressors peripherally to restore mean arterial pressure rather than delaying initiation until a central venous access is secured. Weak; very low quality of evidence NEW
45. There is insufficient evidence to make a recommendation on the use of restrictive versus liberal fluid strategies in the first 24 hr of resuscitation in patients with sepsis and septic shock who still have signs of hypoperfusion and volume depletion after the initial resuscitation. No recommendation NEW
“We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock”
Weak recommendation; low quality of evidence
“We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock.”
Weak recommendation; low quality of evidence
VENTILATION    
46.There is insufficient evidence to make a recommendation on the use of conservative oxygen targets in adults with sepsis-induced hypoxemic respiratory failure. No recommendation  
47. For adults with sepsis-induced hypoxemic respiratory failure, we suggest the use of high flow nasal oxygen over noninvasive ventilation. Weak; low quality of evidence NEW
48. There is insufficient evidence to make a recommendation on the use of noninvasive ventilation in comparison to invasive ventilation for adults with sepsis-induced hypoxemic respiratory failure. No recommendation  
49. For adults with sepsis-induced ARDS, we recommend using a low tidal volume ventilation strategy (6 mL/kg), over a high tidal volume strategy (> 10 mL/kg). Strong; high-quality evidence  
50. For adults with sepsis-induced severe ARDS, we recommend using an upper limit goal for plateau pressures of 30 cm H2O, over higher plateau pressures. Strong; moderate-quality evidence  
51. For adults with moderate to severe sepsis-induced ARDS, we suggest using higher PEEP over lower PEEP. Weak; moderate-quality evidence  
52. For adults with sepsis-induced respiratory failure (without ARDS), we suggest using low tidal volume as compared with high tidal volume ventilation. Weak; low quality of evidence  
53. For adults with sepsis-induced moderate-severe ARDS, we suggest using traditional recruitment maneuvers. Weak; moderate-quality evidence  
54. When using recruitment maneuvers, we recommend against using incremental PEEP titration/strategy. Strong; moderate-quality evidence  
55. For adults with sepsis-induced moderate-severe ARDS, we recommend using prone ventilation for greater than 12 hr daily. Strong; moderate-quality evidence  
56. For adults with sepsis induced moderate-severe ARDS, we suggest using intermittent NMBA boluses, over NMBA continuous infusion. Weak; moderate-quality evidence  
57. For adults with sepsis-induced severe ARDS, we suggest using Veno-venous (VV) ECMO when conventional mechanical ventilation fails in experienced centers with the infrastructure in place to support its use. Weak; low quality of evidence NEW
ADDITIONAL THERAPIES    
58. For adults with septic shock and an ongoing requirement for vasopressor therapy we suggest using IV corticosteroids. Weak; moderate-quality evidence UPGRADE from Weak recommendation , low quality of evidence
“We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (see goals for Initial Resuscitation). If this is not achievable, we suggest IV hydrocortisone at a dose of 200 mg/day.”
59. For adults with sepsis or septic shock we suggest against using polymyxin B hemoperfusion. Weak; low quality of evidence NEW from previous: “We make no recommendation regarding the use of blood purification techniques”
60. There is insufficient evidence to make a recommendation on the use of other blood purification techniques. No recommendation  
61. For adults with sepsis or septic shock we recommend using a restrictive (over liberal) transfusion strategy. Strong; moderate-quality evidence  
62. For adults with sepsis or septic shock we suggest against using IV immunoglobulins. Weak; low quality of evidence  
63. For adults with sepsis or septic shock, and who have risk factors for gastrointestinal (GI) bleeding, we suggest using stress ulcer prophylaxis. Weak; moderate-quality evidence  
64. For adults with sepsis or septic shock, we recommend using pharmacologic venous thromboembolism (VTE) prophylaxis unless a contraindication to such therapy exists. Strong; moderate-quality evidence  
65. For adults with sepsis or septic shock, we recommend using low molecular weight heparin over unfractionated heparin for VTE prophylaxis Strong; moderate-quality evidence  
66. For adults with sepsis or septic shock, we suggest against using mechanical VTE prophylaxis, in addition to pharmacological prophylaxis, over pharmacologic prophylaxis alone. Weak; low quality of evidence  
67. In adults with sepsis or septic shock and AKI, we suggest using either continuous or intermittent renal replacement therapy. Weak; low quality of evidence  
68. In adults with sepsis or septic shock and AKI, with no definitive indications for renal replacement therapy, we suggest against using renal replacement therapy. Weak; moderate-quality evidence  
69. For adults with sepsis or septic shock, we recommend initiating insulin therapy at a glucose level of ≥ 180mg/dL (10 mmol/L). Strong; moderate-quality evidence  
70. For adults with sepsis or septic shock we suggest against using IV vitamin C. Weak; low quality of evidence NEW
71. For adults with septic shock and hypoperfusion-induced lactic acidemia, we suggest against using sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements. Weak; low quality of evidence  
72. For adults with septic shock and severe metabolic acidemia (pH ≤ 7.2) and acute kidney injury (AKIN score 2 or 3), we suggest using sodium bicarbonate therapy Weak; low quality of evidence  
73. For adult patients with sepsis or septic shock who can be fed enterally, we suggest early (within 72 hr) initiation of enteral nutrition. Weak; very low quality of evidence  
LONG-TERM OUTCOMES AND GOALS OF CARE  
74. For adults with sepsis or septic shock, we recommend discussing goals of care and prognosis with patients and families over no such discussion. Best practice statement  
75. For adults with sepsis or septic shock, we suggest addressing goals of care early (within 72 hr) over late (72 hr or later). Weak; low quality of evidence  
76. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation on any specific standardized criterion to trigger goals of care discussion. No recommendation  
77. For adults with sepsis or septic shock, we recommend that the principles of palliative care (which may include palliative care consultation based on clinician judgement) be integrated into the treatment plan, when appropriate, to address patient and family symptoms and suffering. Best practice statement  
78. For adults with sepsis or septic shock, we suggest against routine formal palliative care consultation for all patients over palliative care consultation based on clinician judgement. Weak; low quality of evidence  
79. For adult survivors of sepsis or septic shock and their families, we suggest referral to peer support groups over no such referral. Weak; very low quality of evidence  
80. For adults with sepsis or septic shock, we suggest using a handoff process of critically important information at transitions of care over no such handoff process. Weak; very low quality of evidence  
81. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation on the use of any specific structured handoff tool over usual handoff processes. No recommendation  
82. For adults with sepsis or septic shock and their families, we recommend screening for economic and social support (including housing, nutritional, financial, and spiritual support), and make referrals where available to meet these needs. Best practice statement  
83. For adults with sepsis or septic shock and their families, we suggest offering written and verbal sepsis education (diagnosis, treatment, and post-ICU/post-sepsis syndrome) prior to hospital discharge and in the follow-up setting. Weak; very low quality of evidence  
84. For adults with sepsis or septic shock and their families, we recommend the clinical team provide the opportunity to participate in shared decision making in post-ICU and hospital discharge planning to ensure discharge plans are acceptable and feasible. Best practice statement  
85. For adults with sepsis and septic shock and their families, we suggest using a critical care transition program, compared with usual care, upon transfer to the floor. Weak; very low quality of evidence  
86. For adults with sepsis and septic shock, we recommend reconciling medications at both ICU and hospital discharge. Best practice statement  
87. For adult survivors of sepsis and septic shock and their families, we recommend including information about the ICU stay, sepsis and related diagnoses, treatments, and common impairments after sepsis in the written and verbal hospital discharge summary. Best practice statement  
88. For adults with sepsis or septic shock who developed new impairments, we recommend hospital discharge plans include follow-up with clinicians able to support and manage new and long-term sequelae. Best practice statement  
89. For adults with sepsis or septic shock and their families, there is insufficient evidence to make a recommendation on early post-hospital discharge follow-up compared with routine post-hospital discharge follow-up. No recommendation  
90. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation for or against early cognitive therapy. No recommendation  
91. For adult survivors of sepsis or septic shock, we recommend assessment and follow-up for physical, cognitive, and emotional problems after hospital discharge. Best practice statement  
92. For adult survivors of sepsis or septic shock, we suggest referral to a post-critical illness follow-up program if available. Weak; very low quality of evidence  
93. For adult survivors of sepsis or septic shock receiving mechanical ventilation for > 48hr or an ICU stay of > 72 hr, we suggest referral to a post-hospital rehabilitation program. Weak; very low quality of evidence
 

Medication

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, reduce morbidity, and prevent complications.

Antibiotics, Other

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Imipenem/cilastatin (Primaxin IV)

Imipenem-cilastatin is a carbapenem with activity against most gram-positive organisms (except MRSA), gram-negative organisms, and anaerobes. It is used for treatment of multiple-organism infections in which other agents do not have wide-spectrum coverage or are contraindicated owing to their potential for toxicity.

Meropenem (Merrem)

Meropenem is a carbapenem with slightly increased activity against gram-negative organisms and slightly decreased activity against staphylococci and streptococci compared with imipenem. It is less likely to cause seizures and has superior penetration of the blood-brain barrier compared with imipenem.

Piperacillin and tazobactam (Zosyn)

Piperacillin-tazobactam inhibits the biosynthesis of cell wall mucopeptide and is effective during the stage of active multiplication. It has antipseudomonal activity.

Ampicillin and sulbactam (Unasyn)

Ampicillin and sulbactam is a drug combination of a beta-lactamase inhibitor with ampicillin. It interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. It is an alternative to amoxicillin if the patient is unable to take medications orally. It covers skin, enteric flora, and anaerobes and is not ideal for nosocomial pathogens.

Clindamycin (Cleocin)

Clindamycin is primarily used for its activity against anaerobes. It has some activity against Streptococcus species and methicillin-sensitive S aureus (MSSA).

Metronidazole (Flagyl, Metro)

Metronidazole is an imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. It is usually combined with other antimicrobial agents, except when used for Clostridium difficile enterocolitis, in which monotherapy is appropriate.

Cefepime (Maxipime)

Cefepime is a fourth-generation cephalosporin. It has gram-negative coverage comparable to ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Cefepime is active against Pseudomonas species. It has increased effectiveness against extended-spectrum beta-lactamase (ESBL)–producing organisms. Its poor capacity to cross blood-brain barrier precludes its use for treatment of meningitis.

Levofloxacin (Levaquin)

Levofloxacin is a fluoroquinolone with excellent gram-positive and gram-negative coverage. It is an excellent agent for pneumonia and has excellent abdominal coverage as well. High urine concentration necessitates reduced dosing in urinary tract infection.

Vancomycin

Vancomycin provides gram-positive coverage and good hospital-acquired MRSA coverage. It is now used more frequently because of the high incidence of MRSA. Vancomycin should be given to all septic patients with indwelling catheters or devices. It is advisable for skin and soft-tissue infections.

Trimethoprim/sulfamethoxazole (Bactrim DS, Septra DS)

The broad spectrum and action of trimethoprim and sulfamethoxazole (TMP-SMZ) against organisms found in patients with cystic fibrosis and the convenience of oral administration make this combination useful for treatment of milder infections in an outpatient setting.

Aztreonam (Azactam)

Aztreonam is a monobactam, not a beta-lactam, antibiotic that inhibits cell wall synthesis during bacterial growth. It is active against gram-negative bacilli but has very limited gram-positive activity and is not useful for anaerobes. Aztreonam lacks cross-sensitivity with beta-lactam antibiotics. It may be used in patients who are allergic to penicillins or cephalosporins.

The duration of therapy depends on the severity of infection and is continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. Doses that are smaller than indicated should not be used.

Transient or persistent renal insufficiency may prolong serum levels. After the initial loading dose of 1 or 2 g, reduce the dose by one half for an estimated CrCl of 10-30 mL/min/1.73 m2. When only the serum creatinine concentration is available, the following formula (based on sex, weight, and age) can approximate CrCl (serum creatinine should represent a steady state of renal function):

• Males: CrCl = [(weight in kg)(140 - age)] divided by (72 X serum creatinine in mg/dL)

• Females: 0.85 X above value

In patients with severe renal failure (CrCl < 10 mL/min/1.73 m2), those supported by hemodialysis, a usual dose of 500 mg, 1 g, or 2 g is given initially.

The maintenance dose is one fourth of the usual initial dose given at the usual fixed interval of 6, 8, or 12 hours. For serious or life-threatening infections, supplement maintenance doses with one eighth of the initial dose after each hemodialysis session.

Elderly persons may have diminished renal function. Renal status is a major determinant of dosage in these patients. Serum creatinine may not be an accurate determinant of renal status. Therefore, as with all antibiotics eliminated by the kidneys, obtain estimates of CrCl and make appropriate dosage modifications. Insufficient data are available regarding intramuscular (IM) administration to pediatric patients or dosing in pediatric patients with renal impairment. Aztreonam is administered intravenously only to pediatric patients with normal renal function.

Linezolid (Zyvox)

Linezolid is used as an alternative drug in patients allergic to vancomycin and for treatment of vancomycin-resistant enterococci. It is also effective against MRSA and penicillin-susceptible S pneumoniae infections.

This agent is an oxazolidinone antibiotic that prevents formation of the functional 70S initiation complex, which is essential for the bacterial translation process. Linezolid is bacteriostatic against enterococci and staphylococci and bactericidal against most strains of streptococci.

Ceftriaxone (Rocephin)

Ceftriaxone is a third-generation cephalosporin with broad-spectrum, gram-negative activity. It has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. Ceftriaxone is used for increasing prevalence of penicillinase-producing microorganisms. It inhibits bacterial cell wall synthesis by binding to 1 or more penicillin-binding proteins. Cell wall autolytic enzymes lyse bacteria, while cell wall assembly is arrested.

Daptomycin (Cubicin)

Daptomycin causes membrane depolarization by binding to components of the cell membrane of susceptible organisms. It inhibits DNA, RNA, and protein synthesis intracellularly. It is a bactericidal antibiotic.

Nafcillin (Nallpen)

Nafcillin is a broad-spectrum penicillin. It is used for methicillin-sensitive S aureus and is the initial therapy for suspected penicillin G–resistant streptococcal or staphylococcal infections. In severe infections, start with parenteral therapy and change to oral therapy as the condition warrants. Because of thrombophlebitis, particularly in elderly persons, administer parenterally for only 1-2 days; change to oral therapy as indicated clinically.

Rifampin (Rifadin)

Rifampin is for use in combination with at least 1 other antituberculosis drug. It inhibits RNA synthesis in bacteria by binding to the beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription. Cross-resistance may occur.

Daptomycin (Cubicin)

This is the first of a new antibiotic class called cyclic lipopeptides. It binds to bacterial membranes and causes rapid membrane potential depolarization, thereby inhibiting protein, DNA, and RNA synthesis, and ultimately causing cell death. It is indicated for complicated skin and skin structure infections caused by S aureus (including methicillin-resistant strains), S pyogenes, S agalactiae, S dysgalactiae, and E faecalis (vancomycin-susceptible strains only).

Tigecycline (Tygacil)

Tigecycline is a glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. It inhibits bacterial protein translation by binding to the 30S ribosomal subunit, and it blocks the entry of amino-acyl tRNA molecules in ribosome A site. It is indicated for complicated skin and skin structure infections caused by E coli, E faecalis (vancomycin-susceptible isolates only), S aureus (methicillin-susceptible and -resistant isolates), S agalactiae, S anginosus group (includes S anginosus, S intermedius, and S constellatus), S pyogenes and B fragilis.

 

Questions & Answers

Overview

What is bacterial sepsis?

How is multiple organ dysfunction characterized in bacterial sepsis?

What is the definition of septic shock?

What is pseudosepsis?

What causes bacterial sepsis?

What is the clinical presentation of bacterial sepsis?

Which lab tests are performed in the workup of bacterial sepsis?

Which imaging studies are performed in the workup of bacterial sepsis?

Which cardiac studies are performed in the workup of bacterial sepsis?

Which invasive diagnostic procedures are performed in the workup of bacterial sepsis?

What is the initial treatment for bacterial sepsis?

How does the site of bacterial sepsis affect the selection of empiric antimicrobial therapy?

When is surgery indicated in the treatment of bacterial sepsis?

How are antibiotics selected for the treatment of bacterial sepsis?

When was bacterial sepsis first identified?

When were the guidelines on bacterial sepsis last revised?

What are the organ-specific causes of bacterial sepsis?

What are the noninfectious causes of fever and organ dysfunction that can mimic bacterial sepsis?

What is the pathophysiology of bacterial sepsis?

What is the prognosis of bacterial sepsis?

What is the prognosis of bacterial sepsis in patients with abnormal host immune response?

How does the risk for mortality from bacterial sepsis vary among infection sites?

How does the risk for mortality from bacterial sepsis vary among infection types?

How does antimicrobial therapy affect the prognosis of bacterial sepsis?

Which factors increase the risk of mortality from bacterial sepsis?

Which patient groups have the highest incidence of bacterial sepsis?

Which are the most common organisms causing bacterial sepsis?

What are risk factors for bacterial sepsis and septic shock?

Presentation

What are the general signs and symptoms of bacterial sepsis?

What are the signs and symptoms of respiratory infection in bacterial sepsis?

Which clinical findings are characteristic of GI or GU infection in bacterial sepsis?

Which clinical findings are characteristic of IV line infection in bacterial sepsis?

What are the signs and symptoms of surgical wound infection in bacterial sepsis?

What are the signs and symptoms of end-organ hypoperfusion in bacterial sepsis?

Which clinical findings may be present in bacterial sepsis in the elderly?

Which clinical findings may be present in bacterial sepsis in younger patients?

Which clinical findings are characteristic of bacterial sepsis in patients with chronic hypertension?

Which clinical findings are characteristic of bacterial sepsis during pregnancy?

DDX

How is bacterial sepsis diagnosed?

How is pseudosepsis differentiated from bacterial sepsis?

What are the signs of immunocompromise in bacterial sepsis?

What are the differential diagnoses for Bacterial Sepsis?

Workup

Which studies are included in the workup of bacterial sepsis?

What is the role of CBC count in the workup of bacterial sepsis?

What is the role of complete metabolic profile in the workup of bacterial sepsis?

What is the role of bacterial cultures in the workup of bacterial sepsis?

What is the role of gram staining in the workup of bacterial sepsis?

What is the role of urinalysis in the workup of bacterial sepsis?

What is the role of microbiology in the workup of bacterial sepsis?

Which lab test findings suggest an underlying etiology of bacterial sepsis?

What is the role of PCT measurement in the workup of bacterial sepsis?

What is the role of chest radiography in the workup of bacterial sepsis?

What is the role of chest CT in the workup of bacterial sepsis?

What is the role of ultrasonography in the workup of bacterial sepsis?

What is the role of abdominal CT scanning and MRI in the workup of bacterial sepsis?

What is the role of cardiac studies in the workup of bacterial sepsis?

What is the role of thoracentesis in the workup of bacterial sepsis?

What is the role of surgical incision and drainage in the workup of bacterial sepsis?

What is the role of bronchoscopy in the workup of bacterial sepsis?

What is the role of Swan-Ganz catheterization in the workup of bacterial sepsis?

What is the role of soft tissue imaging studies in the workup of bacterial sepsis?

What is the role of contrast-enhanced CT or MRI in the workup of bacterial sepsis?

Treatment

How is bacterial sepsis treated?

What is the role of surgery in the treatment of bacterial sepsis?

Which specialist consultations are beneficial to patients with bacterial sepsis?

Which antimicrobials are used in empiric monotherapy regimens for the treatment of bacterial sepsis?

What is the role of combination antimicrobial regimens for treatment of bacterial sepsis?

How is catheter-related bacterial sepsis treated?

How is bacterial sepsis in the biliary tract treated?

How is intra-abdominal and pelvic bacterial sepsis treated?

How is urosepsis treated?

How are staphylococcal, pneumococcal, and meningococcal-caused bacterial sepsis treated?

How is bacterial sepsis of unknown origin treated?

What is included in the long-term monitoring of bacterial sepsis?

Guidelines

Which treatment guidelines are available for bacterial sepsis?

Which major new recommendations for the management of bacterial sepsis were published in 2012?

Which major new recommendations for the management of bacterial sepsis were published in 2016?

Medications

What are goals of drug treatment for bacterial sepsis?

Which medications in the drug class Antibiotics, Other are used in the treatment of Bacterial Sepsis?